Ascentage Pharma announced on March 25, 2025, that five abstracts highlighting preclinical results from its pipeline programs were selected for presentation at the 2025 American Association of Cancer Research (AACR) Annual Meeting. The meeting is scheduled for April 25-30, 2025.
The data to be presented covers five novel drug candidates: olverembatinib (HQP1351), lisaftoclax (APG-2575), APG-2449, APG-5918, and AS03157. These presentations will include studies on olverembatinib in combination with lisaftoclax.
This participation at AACR underscores Ascentage Pharma's commitment to advancing its innovative, apoptosis-targeted oncology pipeline. The presentation of preclinical data provides early insights into the potential of its drug candidates and combination therapies.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.